[Federal Register Volume 61, Number 30 (Tuesday, February 13, 1996)]
[Notices]
[Pages 5565-5566]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-3184]



-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing specialist at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804 (telephone 301/496-7057; fax 301/402-0220). A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Antipsychotic Composition and Method for Treatment

Pickar, D., Litman, R.E., Potter, W.Z. (NIMH)
Filed 7 Jun 95
Serial No. 08/479,039 (CIP of 07/987,728)
Licensing Contact: Stephen Finley, 301/496-7735 ext 215

    This invention comprises a novel treatment method for patients 
suffering from serious psychotic mental illness that offers to 
significantly improve the treatment of such illnesses. Conventional 
antipsychotic drugs are effective in improving symptoms of 
schizophrenia, but a significant number of patients have proven 
resistant to such treatments. Recently, the drug clozapine has been 
found effective in treating such drug-resistant patients; however, 
clozapine has severe toxic side effects. This newly developed treatment 
method, which combines the use of an 2-adrenergic 
receptor antagonist with a standard antipsychotic drug, is effective in 
treating psychosis without serious side effects. It is especially 
effective in patients who previously had been resistant to treatment 
with standard antipsychotic drugs alone. (portfolio: Central Nervous 
System--Therapeutics, psychotherapeutics, antipsychotics)

Amino Acid Sequencing Peptides and Methods for Their Use

Parmelee, D.C., Sechi, S. (NCI)
Filed 6 Feb 95
Serial No. 08/384,212 (DIV of 07/920,130)
Licensing Contact: J. Peter Kim, 301/496-7056 ext 264

    The present invention provides a novel internal standard for amino 
acid sequencing which consist of a peptide containing at least two 
different unnatural amino acid residues, such as ornithine, norvaline, 
norleucine and -aminobutyric acid. The PTH-derivatives of 
these have retention times distinct from those of natural amino acids. 
This peptide can be sequenced simultaneously with an unknown peptide or 
protein without interfering with the analysis. Simultaneous sequencing 
of this standard provides information which allows for the 
determination of repetitive yields, lags, N-terminal blockage and 
discrimination between blank cycles caused by missed injection and 
blank cycles caused by faulty delivery of chemicals during the 
sequencing reactions. (portfolio: Gene-

[[Page 5566]]
Based Therapies--Research Tools and Reagents)

4' -and 4',4''-Substituted-3(Diphenylmethoxy)Tropane Analogs 
as Cocaine Therapeutics

Newman, A.H., Allen, A.C., Kline, R.H., Izenwasser, S., Katz, J.L. 
(NIDA)
Filed 21 Jun 95
Serial No. 60/000,378
Licensing Contact: Leopold J. Luberecki, Jr., 301/496-7735 ext 223

    The invention provides a series of 4'- and 4',4''-substituted 
benztropine analogs that demonstrate high affinity binding 
(K1<30nM) to the dopamine transporter and bind selectively (>100-
fold) over the other monoamine transporters. These compounds block 
dopamine reuptake in vitro and yet do not demonstrate a cocaine-like 
behavioral profile in animal models of psychomotor stimulant abuse. 
Structure-Activity Relationships suggest that these compounds interact 
at a binding domain that differs from that of cocaine at the dopamine 
transporter. These compounds represent an unprecedented class of 
dopamine uptake inhibitors that may have potential as cocaine-abuse 
therapeutics, since they have neurochemical similarities to cocaine and 
yet do not appear to have abuse liability. Further, radiolabeled 
analogs will be suitable for imaging the dopamine transporter in 
mammalian brain using SPECT and PET and thus would be useful in the 
diagnoses and monitoring of neurodegenerative disorders involving the 
dopaminergic system (e.g., Parkinson's disease). In addition, the 
invention provides pharmaceutical compositions comprising an analog of 
the invention and a pharmaceutically acceptable carrier excipient. 
(portfolio: Central Nervous System--Therapeutics, psychotherapeutics, 
drug dependence; Central Nervous System--Therapeutics, neurological, 
antiparkinsonian)

Alzheimer's Disease Index (ADI)

Alkon, D.L. (NINDS)
Filed 26 Sep 95
DHHS Reference No. E-092-93/2
Licensing Contact: Stephen Finley, 301/496-7735 ext 215

    Under currently available technology, Alzheimer's disease can only 
be presumptively diagnosed by pathological examination of brain tissue 
during autopsy in conjunction with a clinical history of dementia. The 
present invention provides a highly reliable laboratory method of 
identifying Alzheimer's disease in a patient. The method consists of: 
measuring the presence or absence of a specific potassium channel, 
measuring the effect of potassium channel blockers specific for the 113 
pS potassium channel on intracellular calcium levels, measuring the 
increase of intracellular calcium in response to an activator of 
intracellular calcium release in the cells of a patient, and measuring 
the amount of the G-protein, cp20. An index calculated on the basis of 
any two of these four tests identifies Alzheimer's disease with very 
high sensitivity and specificity (n=100, initial sample) in comparisons 
between Alzheimer's disease patients and other non-Alzheimer's 
dementias as well as age-matched controls. (portfolio: Central Nervous 
System--Diagnostics, in vitro, other).

    Dated: February 6, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-3184 Filed 2-12-96; 8:45 am]
BILLING CODE 4140-01-M